BCRXBioCryst Pharmaceuticals, Inc.

1. Aug 5, 2026BioCryst Reports Second Quarter 2026 Financial Results.Earnings release · press release
2. Aug 4, 2026The Original Report otherwise remains unchanged.Exit or disposal costs (restructuring) · Form 8-K/A
3. Jun 29, 2026On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”)Exit or disposal costs (restructuring) · Form 8-K
4. Jun 12, 2026Amended and Restated Stock Incentive Plan On June 11, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved, by the affirmative vote of a majority of the shares of the Company’s common stock …Director or officer change · Form 8-K
5. Jan 23, 2026On January 23, 2026 (the “Closing Date”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”) completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the “Merger Agreement”), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a …Director or officer change · Form 8-K/A
6. Jan 23, 2026On January 23, 2026 (the “Closing Date”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”), entered into a Loan Agreement (the “Loan Agreement”), by and among BioCryst, as borrower, the guarantors from time to time party thereto, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences …Material agreement entered · Form 8-K
7. Jan 12, 2026As announced in the Press Release: · Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2025 was $151 million (+22 percent year-over-year; +36% year-over-year on a comparable basis, excluding European ORLADEYO revenue for the fourth quarter of 2024). · Preliminary, unaudited ORLADEYO net revenue for …Earnings release · Form 8-K
8. Dec 12, 2025On December 12, 2025, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s new drug application for the use of an oral pellet formulation of once-daily ORLADEYO ® (berotralstat) for prophylactic therapy in pediatric …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.